Gonadal recovery following hematopoietic stem cell transplantation in female patients
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 103 | 24 (13–58) | 3 (1–17) | 54% | 44 live births, 4 spontaneous abortions, 5 elective abortions and 2 tubal pregnancies in 56 pregnancies of 28 patients | (21) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 21 (13–46) | 4 (1–14) | 27% | 8 live births, 6 spontaneous abortions and 2 elective abortions in | (21) |
| CY/TBI (12 Gy) | HM | 270 | 33 (11–58) | 3 (1–13) | 10% | 16 pregnancies of 13 patients | ||
| CY/TBI (>12 Gy) | HM | 203 | 33 (15–57) | 3 (1–10) | 5% | |||
| Allogeneic | TBI (8.5–13.2) based regimen | HM | 79 | NA | 4 (0.3–10) | 13.5% (>18 years), 100%(<18 years) | 1 live birth in 1 patient | (66) |
| Allogeneic | BU/CY | HM | 73 | 24 (14–57) | 2 (1–6) | 1% | No pregnancy in 1 patient | (21) |
| Allogeneic | FDR/MEL ± ETP ± CA ± TBI (3–4 Gy) | HM | 11 | 10 (1–18) | 8 (3–14) | 82% | NA | (67) |
| Allogeneic | FDR/MEL ± ATG | EBV-LPD, HM | 11 | 25 (15–38) at the examination | NA | 82% | NA | (68) |
| Autologous | BEAM | HL, NHL | 25 | 27 (17–40) | 8 (2–17) | 68% | 12 live births, 1 spontaneous abortion and 2 current pregnancies in 15 pregnancies of 10 patients | (69) |
| Autologous | MEL ± ETP | HL, NHL | 30 | 77% younger than 40 years | NA | NA | 16 live births (2 twins and 1 triplets) in 12 pregnancies of 10 patients. Abortions were not fully assessed. | (70) |
| Allogeneic Autologous Syngeneic | CY/TBI with OS or CA/TBI with OS | HM, AA | 19 | 23 (19–33) | 4 (0.2–10) | 78% | 2 live births, 2 spontaneous abortions and 1 current pregnancy in 5 pregnancies of 3 patients | (62) |
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 103 | 24 (13–58) | 3 (1–17) | 54% | 44 live births, 4 spontaneous abortions, 5 elective abortions and 2 tubal pregnancies in 56 pregnancies of 28 patients | (21) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 21 (13–46) | 4 (1–14) | 27% | 8 live births, 6 spontaneous abortions and 2 elective abortions in | (21) |
| CY/TBI (12 Gy) | HM | 270 | 33 (11–58) | 3 (1–13) | 10% | 16 pregnancies of 13 patients | ||
| CY/TBI (>12 Gy) | HM | 203 | 33 (15–57) | 3 (1–10) | 5% | |||
| Allogeneic | TBI (8.5–13.2) based regimen | HM | 79 | NA | 4 (0.3–10) | 13.5% (>18 years), 100%(<18 years) | 1 live birth in 1 patient | (66) |
| Allogeneic | BU/CY | HM | 73 | 24 (14–57) | 2 (1–6) | 1% | No pregnancy in 1 patient | (21) |
| Allogeneic | FDR/MEL ± ETP ± CA ± TBI (3–4 Gy) | HM | 11 | 10 (1–18) | 8 (3–14) | 82% | NA | (67) |
| Allogeneic | FDR/MEL ± ATG | EBV-LPD, HM | 11 | 25 (15–38) at the examination | NA | 82% | NA | (68) |
| Autologous | BEAM | HL, NHL | 25 | 27 (17–40) | 8 (2–17) | 68% | 12 live births, 1 spontaneous abortion and 2 current pregnancies in 15 pregnancies of 10 patients | (69) |
| Autologous | MEL ± ETP | HL, NHL | 30 | 77% younger than 40 years | NA | NA | 16 live births (2 twins and 1 triplets) in 12 pregnancies of 10 patients. Abortions were not fully assessed. | (70) |
| Allogeneic Autologous Syngeneic | CY/TBI with OS or CA/TBI with OS | HM, AA | 19 | 23 (19–33) | 4 (0.2–10) | 78% | 2 live births, 2 spontaneous abortions and 1 current pregnancy in 5 pregnancies of 3 patients | (62) |
FDR, fludarabine; MEL, melphalan; ETP, etoposide; CA, cytarabine; ATG, anti-thymocyte globulin; EBV-LPD, Epstein–Barr virus-associated lymphoproliferative disease; OS ovarian shielding.
Gonadal recovery following hematopoietic stem cell transplantation in female patients
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 103 | 24 (13–58) | 3 (1–17) | 54% | 44 live births, 4 spontaneous abortions, 5 elective abortions and 2 tubal pregnancies in 56 pregnancies of 28 patients | (21) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 21 (13–46) | 4 (1–14) | 27% | 8 live births, 6 spontaneous abortions and 2 elective abortions in | (21) |
| CY/TBI (12 Gy) | HM | 270 | 33 (11–58) | 3 (1–13) | 10% | 16 pregnancies of 13 patients | ||
| CY/TBI (>12 Gy) | HM | 203 | 33 (15–57) | 3 (1–10) | 5% | |||
| Allogeneic | TBI (8.5–13.2) based regimen | HM | 79 | NA | 4 (0.3–10) | 13.5% (>18 years), 100%(<18 years) | 1 live birth in 1 patient | (66) |
| Allogeneic | BU/CY | HM | 73 | 24 (14–57) | 2 (1–6) | 1% | No pregnancy in 1 patient | (21) |
| Allogeneic | FDR/MEL ± ETP ± CA ± TBI (3–4 Gy) | HM | 11 | 10 (1–18) | 8 (3–14) | 82% | NA | (67) |
| Allogeneic | FDR/MEL ± ATG | EBV-LPD, HM | 11 | 25 (15–38) at the examination | NA | 82% | NA | (68) |
| Autologous | BEAM | HL, NHL | 25 | 27 (17–40) | 8 (2–17) | 68% | 12 live births, 1 spontaneous abortion and 2 current pregnancies in 15 pregnancies of 10 patients | (69) |
| Autologous | MEL ± ETP | HL, NHL | 30 | 77% younger than 40 years | NA | NA | 16 live births (2 twins and 1 triplets) in 12 pregnancies of 10 patients. Abortions were not fully assessed. | (70) |
| Allogeneic Autologous Syngeneic | CY/TBI with OS or CA/TBI with OS | HM, AA | 19 | 23 (19–33) | 4 (0.2–10) | 78% | 2 live births, 2 spontaneous abortions and 1 current pregnancy in 5 pregnancies of 3 patients | (62) |
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 103 | 24 (13–58) | 3 (1–17) | 54% | 44 live births, 4 spontaneous abortions, 5 elective abortions and 2 tubal pregnancies in 56 pregnancies of 28 patients | (21) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 21 (13–46) | 4 (1–14) | 27% | 8 live births, 6 spontaneous abortions and 2 elective abortions in | (21) |
| CY/TBI (12 Gy) | HM | 270 | 33 (11–58) | 3 (1–13) | 10% | 16 pregnancies of 13 patients | ||
| CY/TBI (>12 Gy) | HM | 203 | 33 (15–57) | 3 (1–10) | 5% | |||
| Allogeneic | TBI (8.5–13.2) based regimen | HM | 79 | NA | 4 (0.3–10) | 13.5% (>18 years), 100%(<18 years) | 1 live birth in 1 patient | (66) |
| Allogeneic | BU/CY | HM | 73 | 24 (14–57) | 2 (1–6) | 1% | No pregnancy in 1 patient | (21) |
| Allogeneic | FDR/MEL ± ETP ± CA ± TBI (3–4 Gy) | HM | 11 | 10 (1–18) | 8 (3–14) | 82% | NA | (67) |
| Allogeneic | FDR/MEL ± ATG | EBV-LPD, HM | 11 | 25 (15–38) at the examination | NA | 82% | NA | (68) |
| Autologous | BEAM | HL, NHL | 25 | 27 (17–40) | 8 (2–17) | 68% | 12 live births, 1 spontaneous abortion and 2 current pregnancies in 15 pregnancies of 10 patients | (69) |
| Autologous | MEL ± ETP | HL, NHL | 30 | 77% younger than 40 years | NA | NA | 16 live births (2 twins and 1 triplets) in 12 pregnancies of 10 patients. Abortions were not fully assessed. | (70) |
| Allogeneic Autologous Syngeneic | CY/TBI with OS or CA/TBI with OS | HM, AA | 19 | 23 (19–33) | 4 (0.2–10) | 78% | 2 live births, 2 spontaneous abortions and 1 current pregnancy in 5 pregnancies of 3 patients | (62) |
FDR, fludarabine; MEL, melphalan; ETP, etoposide; CA, cytarabine; ATG, anti-thymocyte globulin; EBV-LPD, Epstein–Barr virus-associated lymphoproliferative disease; OS ovarian shielding.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
